Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone
- 1 February 2004
- journal article
- clinical trial
- Published by Elsevier BV in Diabetes Research and Clinical Practice
- Vol. 63 (2), 127-134
- https://doi.org/10.1016/j.diabres.2003.09.004
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
This publication has 11 references indexed in Scilit:
- Insulin resistance syndrome and type 2 diabetes mellitusThe American Journal of Cardiology, 2001
- Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled studyAmerican Journal Of Medicine, 2001
- Dyslipidaemia and diabetesPractical Diabetes International, 2001
- New Oral Therapies for Type 2 Diabetes Mellitus: The Glitazones or Insulin SensitizersAnnual Review of Medicine, 2001
- Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.Diabetes Care, 2000
- Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetesInternational Journal of Obesity, 2000
- Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.Diabetes Care, 2000
- Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve‐week, randomized, placebo‐controlled studyDiabetes, Obesity and Metabolism, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998